Increased natriuretic peptide receptor A and C gene expression in rats with pressure-overload cardiac hypertrophy

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 290, Issue 4, 2006, Pages

  Christoffersen, Tue E H ^a   Aplin, Mark ^a   Strom, Claes C ^a   Sheikh, Soren P ^a   Skott, Ole ^c   Busk, Peter K ^b   Haunso, Stig ^a   Nielsen, Lars B ^a  

^a Rigshospitalet   (Denmark)

^b NOVO NORDISK A S   (Denmark)

^c UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

Angiotensin II type 1 receptor; Losartan; Renin

Indexed keywords

ATRIAL NATRIURETIC FACTOR; BRAIN NATRIURETIC PEPTIDE; HORMONE RECEPTOR; HYPNORM; ISOFLURANE; LOSARTAN; MESSENGER RNA; MIDAZOLAM MALEATE; NATRIURETIC FACTOR; PLACEBO; PROTEIN NATRIURETIC PEPTIDE RECEPTOR A; PROTEIN NATRIURETIC PEPTIDE RECEPTOR C; RENIN; UNCLASSIFIED DRUG; ATRIAL NATRIURETIC FACTOR RECEPTOR; ATRIAL NATRIURETIC FACTOR RECEPTOR A; ATRIAL NATRIURETIC FACTOR RECEPTOR C; GUANYLATE CYCLASE;

ANESTHESIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASCENDING AORTA; CONTROLLED STUDY; GENE EXPRESSION; HEART LEFT VENTRICLE; HEART VENTRICLE HYPERTROPHY; HEART VENTRICLE OVERLOAD; HEART WEIGHT; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; UPREGULATION; ANIMAL; GENE EXPRESSION REGULATION; HEART LEFT VENTRICLE HYPERTROPHY; HEART VENTRICLE; METABOLISM; WISTAR RAT;

ANIMALS; GENE EXPRESSION REGULATION; GUANYLATE CYCLASE; HEART VENTRICLES; HYPERTROPHY, LEFT VENTRICULAR; MALE; RATS; RATS, WISTAR; RECEPTORS, ATRIAL NATRIURETIC FACTOR; RENIN-ANGIOTENSIN SYSTEM;

EID: 33646094735     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.00612.2005     Document Type: Article

References (52)

1. Aceto JF and Baker KM. [Sar1]angiotensin II receptor-mediated stimulation of protein synthesis in chick heart cells. Am J Physiol Heart Circ Physiol 258: H806-H813, 1990.
2. Anand-Srivastava MB. Natriuretic peptide receptor-C signaling and regulation. Peptides 26: 1044-1059, 2005.
3. Andreassi MG, Del Ry S, Palmieri C, Clerico A, Biagini A, and Giannessi D. Up-regulation of "clearance" receptors in patients with chronic heart failure: a possible explanation for the resistance to biological effects of cardiac natriuretic hormones. Eur J Heart Fail 3: 407-414, 2001.
4. Brown LA, Nunez DJ, and Wilkins MR. Differential regulation of natriuretic peptide receptor messenger RNAs during the development of cardiac hypertrophy in the rat. J Clin Invest 92: 2702-2712, 1993.
5. Bruckschlegel G, Holmer SR, Jandeleit K, Grimm D, Muders F, Kromer EP, Riegger GA, and Schunkert H. Blockade of the renin-angiotensin system in cardiac pressure-overload hypertrophy in rats. Hypertension 25: 250-259, 1995.
6. Cao L and Gardner DG. Natriuretic peptides inhibit DNA synthesis in cardiac fibroblasts. Hypertension 25: 227-234, 1995.
7. Cao L, Wu J, and Gardner DG. Atrial natriuretic peptide suppresses the transcription of its guanylyl cyclase-linked receptor. J Biol Chem 270: 24891-24897, 1995.
8. Christoffersen C, Goetze JP, Bartels ED, Larsen MO, Ribel U, Rehfeld JF, Rolin B, and Nielsen LB. Chamber-dependent expression of brain natriuretic peptide and its mRNA in normal and diabetic pig heart. Hypertension 40: 54-60, 2002.
9. Corti R, Burnett JC Jr, Rouleau JL, Ruschitzka F, and Luscher TF. Vasopeptidase inhibitors: a new therapeutic concept in cardiovascular disease? Circulation 104: 1856-1862, 2001.
10. -/- mice with cardiac hypertrophy and fibrosis. Am J Physiol Heart Circ Physiol 283: H707-H714, 2002.
11. Erdos EG and Skidgel RA. Neutral endopeptidase 24.11 (enkephalinase) and related regulators of peptide hormones. FASEB J 3: 145-151, 1989.
12. Feldman AM, Weinberg EO, Ray PE, and Lorell BH. Selective changes in cardiac gene expression during compensated hypertrophy and the transition to cardiac decompensation in rats with chronic aortic banding. Circ Res 73: 184-192, 1993.
13. Goetze JP, Christoffersen C, Perko M, Arendrup H, Rehfeld JF, Kastrup J, and Nielsen LB. Increased cardiac BNP expression associated with myocardial ischemia. FASEB J 17: 1105-1107, 2003.
14. Goetze JP, Gore A, Moller CH, Steinbruchel DA, Rehfeld JF, and Nielsen LB. Acute myocardial hypoxia increases BNP gene expression. FASEB J 18: 1928-1930, 2004.
15. Gu J, D'Andrea M, Seethapathy M, McDonnell C, and Cichon R. Physical overdistension converts ventricular cardiomyocytes to acquire endocrine property and regulate ventricular atrial natriuretic peptide production. Angiology 42: 173-186, 1991.
16. Holtwick R, Baba HA, Ehler E, Risse D, Vobeta M, Gehrmann J, Pierkes M, and Kuhn M. Left but not right cardiac hypertrophy in atrial natriuretic peptide receptor-deficient mice is prevented by angiotensin type 1 receptor antagonist losartan. J Cardiovasc Pharmacol 40: 725-734, 2002.
17. Horio T, Tokudome T, Maki T, Yoshihara F, Suga S, Nishikimi T, Kojima M, Kawano Y, and Kangawa K. Gene expression, secretion, and autocrine action of C-type natriuretic peptide in cultured adult rat cardiac fibroblasts. Endocrinology 144: 2279-2284, 2003.
18. Hystad ME, Geiran OR, Attramadal H, Spurkland A, Vege A, Simonsen S, and Hall C. Regional cardiac expression and concentration of natriuretic peptides in patients with severe chronic heart failure. Acta Physiol Scand 171: 395-403, 2001.
19. Iso T, Arai M, Wada A, Kogure K, Suzuki T, and Nagai R. Humoral factor(s) produced by pressure overload enhance cardiac hypertrophy and natriuretic peptide expression. Am J Physiol Heart Circ Physiol 273: H113-H118, 1997.
20. Izumi T, Saito Y, Kishimoto I, Harada M, Kuwahara K, Hamanaka I, Takahashi N, Kawakami R, Li Y, Takemura G, Fujiwara H, Garbers DL, Mochizuki S, and Nakao K. Blockade of the natriuretic peptide receptor guanylyl cyclase-A inhibits NF-κB activation and alleviates myocardial ischemia/reperfusion injury. J Clin Invest 108: 203-213, 2001.
21. Jin H, Li B, Cunningham B, Tom J, Yang R, Sehl P, Thomas GR, Ko A, Oare D, and Lowe DG. Novel analog of atrial natriuretic peptide selective for receptor-A produces increased diuresis and natriuresis in rats. J Clin Invest 98: 969-976, 1996.
22. John SW, Krege JH, Oliver PM, Hagaman JR, Hodgin JB, Pang SC, Flynn TG, and Smithies O. Genetic decreases in atrial natriuretic peptide and salt-sensitive hypertension. Science 267: 679-681, 1995.
23. John SW, Veress AT, Honrath U, Chong CK, Peng L, Smithies O, and Sonnenberg H. Blood pressure and fluid-electrolyte balance in mice with reduced or absent ANP. Am J Physiol Regul Integr Comp Physiol 271: R109-R114, 1996.
24. Kalra PR, Clague JR, Bolger AP, Anker SD, Poole-Wilson PA, Struthers AD, and Coats AJ. Myocardial production of C-type natriuretic peptide in chronic heart failure. Circulation 107: 571-573, 2003.
25. Kromer EP, Elsner D, and Riegger GA. Role of neurohumoral systems for pressure induced left ventricular hypertrophy in experimental supravalvular aortic stenosis in rats. Am J Hypertens 4: 521-524, 1991.
26. Kromer EP and Riegger GA. Effects of long-term angiotensin converting enzyme inhibition on myocardial hypertrophy in experimental aortic stenosis in the rat. Am J Cardiol 62: 161-163, 1988.
27. Lee J, Kim S, Jung M, Oh Y, and Kim SW. Altered expression of vascular natriuretic peptide receptors in experimental hypertensive rats. Clin Exp Pharmacol Physiol 29: 299-303, 2002.
28. Levy D, Garrison RJ, Savage DD, Kannel WB, and Castelli WP. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 322: 1561-1566, 1990.
29. Lin X, Hanze J, Heese F, Sodmann R, and Lang RE. Gene expression of natriuretic peptide receptors in myocardial cells. Circ Res 77: 750-758, 1995.
30. Litwin SE, Katz SE, Weinberg EO, Lorell BH, Aurigemma GP, and Douglas PS. Serial echocardiographic-Doppler assessment of left ventricular geometry and function in rats with pressure-overload hypertrophy. Chronic angiotensin-converting enzyme inhibition attenuates the transition to heart failure. Circulation 91: 2642-2654, 1995.
31. Lykkegard S and Poulsen K. Ultramicroassay for plasma renin concentration in the rat using the antibody-trapping technique. Anal Biochem 75: 250-259, 1976.
32. Maack T, Suzuki M, Almeida FA, Nussenzveig D, Scarborough RM, McEnroe GA, and Lewicki JA. Physiological role of silent receptors of atrial natriuretic factor. Science 238: 675-678, 1987.
33. Magga J, Kalliovalkama J, Romppanen H, Vuolteenaho O, Porsti I, Kahonen M, Tolvanen JP, and Ruskoaho H. Differential regulation of cardiac adrenomedullin and natriuretic peptide gene expression by AT1 receptor antagonism and ACE inhibition in normotensive and hypertensive rats. J Hypertens 17: 1543-1552, 1999.
34. Matsukawa N, Grzesik WJ, Takahashi N, Pandey KN, Pang S, Yamauchi M, and Smithies O. The natriuretic peptide clearance receptor locally modulates the physiological effects of the natriuretic peptide system. Proc Natl Acad Sci USA 96: 7403-7408, 1999.
35. McMullen JR, Sherwood MC, Tarnavski O, Zhang L, Dorfman AL, Shioi T, and Izumo S. Inhibition of mTOR signaling with rapamycin regresses established cardiac hypertrophy induced by pressure overload. Circulation 109: 3050-3055, 2004.
36. Ogawa T, Linz W, Stevenson M, Bruneau BG, Kuroski de Bold ML, Chen JH, Eid H, Scholkens BA, and de Bold AJ. Evidence for load-dependent and load-independent determinants of cardiac natriuretic peptide production. Circulation 93: 2059-2067, 1996.
37. Ogawa Y, Itoh H, Tamura N, Suga S, Yoshimasa T, Uehira M, Matsuda S, Shiono S, Nishimoto H, and Nakao K. Molecular cloning of the complementary DNA and gene that encode mouse brain natriuretic peptide and generation of transgenic mice that overexpress the brain natriuretic peptide gene. J Clin Invest 93: 1911-1921, 1994.
38. Patel JB, Valencik ML, Pritchett AM, Burnett JC Jr, McDonald JA, and Redfield MM. Cardiac-specific attenuation of natriuretic peptide A receptor activity accentuates adverse cardiac remodeling and mortality in response to pressure overload. Am J Physiol Heart Circ Physiol 289: H777-H784, 2005.
39. Qi W, Mathisen P, Kjekshus J, Simonsen S, Bjornerheim R, Endresen K, and Hall C. Natriuretic peptides in patients with aortic stenosis. Am Heart J 142: 725-732, 2001.
40. Rademaker MT, Charles CJ, Kosoglou T, Protter AA, Espiner EA, Nicholls MG, and Richards AM. Clearance receptors and endopeptidase: equal role in natriuretic peptide metabolism in heart failure. Am J Physiol Heart Circ Physiol 273: H2372-H2379, 1997.
41. Sadoshima J, Xu Y, Slayter HS, and Izumo S. Autocrine release of angiotensin II mediates stretch-induced hypertrophy of cardiac myocytes in vitro. Cell 75: 977-984, 1993.
42. Schunkert H, Weinberg EO, Bruckschlegel G, Riegger AJ, and Lorell BH. Alteration of growth responses in established cardiac pressure overload hypertrophy in rats with aortic banding. J Clin Invest 96: 2768-2774, 1995.
43. Strom CC, Kruhoffer M, Knudsen S, Stensgaard-Hansen F, Jonassen TEN, Orntoft TF, Haunso S, and Sheikh SP. Identification of a core set of genes that signifies pathways underlying cardiac hypertrophy. Comp Funct Genomics 5: 459-470, 2004.
44. Su X, Brower G, Janicki JS, Chen YF, Oparil S, and Dell'Italia LJ. Differential expression of natriuretic peptides and their receptors in volume overload cardiac hypertrophy in the rat. J Mol Cell Cardiol 31: 1927-1936, 1999.
45. Suga S, Nakao K, Hosoda K, Mukoyama M, Ogawa Y, Shirakami G, Arai H, Saito Y, Kambayashi Y, and Inouye K. Receptor selectivity of natriuretic peptide family, atrial natriuretic peptide, brain natriuretic peptide, and C-type natriuretic peptide. Endocrinology 130: 229-239, 1992.
46. Tamura N, Ogawa Y, Chusho H, Nakamura K, Nakao K, Suda M, Kasahara M, Hashimoto R, Katsuura G, Mukoyama M, Itoh H, Saito Y, Tanaka I, Otani H, and Katsuki M. Cardiac fibrosis in mice lacking brain natriuretic peptide. Proc Natl Acad Sci USA 97: 4239-4244, 2000.
47. Timmermans PB and Smith RD. The diversified pharmacology of angiotensin II-receptor blockade. Blood Press Suppl 2: 53-61, 1996.
48. Weinberg EO, Schoen FJ, George D, Kagaya Y, Douglas PS, Litwin SE, Schunkert H, Benedict CR, and Lorell BH. Angiotensin-converting enzyme inhibition prolongs survival and modifies the transition to heart failure in rats with pressure overload hypertrophy due to ascending aortic stenosis. Circulation 90: 1410-1422, 1994.
49. Wilcox JN, Augustine A, Goeddel DV, and Lowe DG. Differential regional expression of three natriuretic peptide receptor genes within primate tissues. Mol Cell Biol 11: 3454-3462, 1991.
50. Wong PC, Price WA, Chiu AT, Duncia JV, Carini DJ, Wexler RR, Johnson AL, and Timmermans PB. Nonpeptide angiotensin II receptor antagonists. VIII. Characterization of functional antagonism displayed by DuP 753, an orally active antihypertensive agent. J Pharmacol Exp Ther 252: 719-725, 1990.
51. Wong PC, Price WA Jr, Chiu AT, Duncia JV, Carini DJ, Wexler RR, Johnson AL, and Timmermans PB. In vivo pharmacology of DuP 753. Am J Hypertens 4: 288S-298S, 1991.
52. Yamamoto K, Burnett JC Jr, Jougasaki M, Nishimura RA, Bailey KR, Saito Y, Nakao K, and Redfield MM. Superiority of brain natriuretic peptide as a hormonal marker of ventricular systolic and diastolic dysfunction and ventricular hypertrophy. Hypertension 28: 988-994, 1996.